IMMULOGIC Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMMULOGIC

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bhag Karamchandani who wrote ()	1/6/1997 9:45:00 PM
From: Jeffers Hughes	of 305

Monday January 6 5:50 PM EST Immulogic Pharmaceutical Corp files for peptide therapy trial WALTHAM, Mass., Jan 7 (Reuter) - ImmuLogic Pharmaceuticals Corp said Monday it filed an investigational new drug application with the U.S. Food and Drug Administration to begin human clinical trials for its multiple sclerosis peptide therapeutic. ImmuLogic said it planned to begin a phase I trial in the second quarter, after completing the final manufacturing process for the clinical grade product which would be used in the trial. Marr, acting president and chief executive officer, said: "This IND filing is our first step in expanding the clinical application of our core technology of tolerance induction beyond allergy and into the autoimmune disease arena." ImmuLogic is a biopharmaceutical company which develops peptide therapeutics to treat allergies and autoimmune diseases. It is also working on a poison ivy and poison oak therapeutic and a vaccine to treat cocaine abuse. The company said its multiple sclerosis therapeutic was aimed at turning off cells which trigger the inflammatory response that destroys the myelin sheath surrounding nerves. It said it was developing the therapeutic in collaboration with Schering AG SCHG.F .

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next